EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Importance of Non-Cardiovascular Comorbidities in Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction

Yasuhiro Hamatani, Moritake Iguchi, Takao Kato, Yasutaka Inuzuka, Yodo Tamaki, Neiko Ozasa, Tetsuma Kawaji, Masahiro Esato, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe und 4 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15093 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Yasuhiro Hamatani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Failure, Stroke Volume, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, Bayer Healthcare, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atrial fibrillation (AF) and heart failure (HF) with preserved ejection fraction (HFpEF) are interlinked and frequently coexisting conditions. To date, patients with AF and HFpEF have limited evidence guiding their management. This study aimed to investigate the predictors of adverse outcomes among patients with AF and HFpEF.

Methods

The Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Kyoto, Japan. From the registry, we explored predictors for a composite of cardiac death or HF hospitalization among AF patients with HFpEF (defined as having a prior HF hospitalization or New York Heart Association class ≥2 in association with heart disease and left ventricular ejection fraction ≥50%). Besides, we investigated whether the scoring using the predictors identified by the Fushimi AF Registry could stratify the outcomes in patients with AF and HFpEF registered in another independent Kyoto Congestive Heart Failure Registry.

Results

Of 755 patients with AF and HFpEF [mean age: 77.5 ± 9.9 years; female: 391 (52%); paroxysmal AF: 258 (34%); and mean CHA2DS2-VASc score: 4.5 ± 1.5], cardiac death or HF hospitalization occurred in 246 patients (33%) during the median follow-up period of 4.4 years in the Fushimi AF Registry. Using multivariate Cox regression analysis, age ≥75 years [hazard ratio (HR): 1.72, 95% confidence interval (CI): 1.26–2.36] and non-cardiovascular comorbidities such as anaemia (HR: 1.83, 95% CI: 1.37–2.46), chronic kidney disease (HR: 1.69, 95% CI: 1.27–2.26), diabetes mellitus (HR: 1.55, 95% CI: 1.15–2.09) and chronic obstructive pulmonary disease (HR: 1.87, 95% CI: 1.08–3.22) were independent predictors of adverse outcomes. Meanwhile, cardiovascular comorbidities including coronary artery disease, valvular heart disease or cardiomyopathy were not significantly associated with adverse outcomes. These results were also the case when analysed for patients with AF and HFpEF who registered in the Kyoto Congestive Heart Failure registry (N = 878). The score assigning 1 point for each five predictors (age, anaemia, chronic kidney disease, diabetes mellitus and chronic obstructive pulmonary disease; ranging 0–5 points) stratified the incidence of adverse outcomes among patients with AF and HFpEF registered in the Kyoto Congestive Heart Failure Registry as well as among those in the Fushimi AF Registry (both log-rank; P < 0.001).

Conclusions

Non-cardiovascular comorbidities such as anaemia, diabetes mellitus and kidney or pulmonary disease in addition to advanced age were independent predictors of adverse outcomes in patients with AF and HFpEF. Our study suggests the importance of focusing on these non-cardiovascular comorbidities for individualized risk stratification and optimal management in patients with AF and HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHeart FailureStroke VolumeRegistriesVentricular Function, LeftHumansFemaleMaleAgedComorbidityProspective StudiesJapanFollow-Up StudiesAged, 80 and overHospitalizationRisk FactorsPrognosis

Stichwörter der Autor:innen

atrial fibrillationcomorbiditiesheart failurepreserved ejection fraction

Autor:innen und Institutionen

  • Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  • Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Cardiovascular Medicine, Shiga Medical Center for Adults, Moriyama, Japan.
  • Division of Cardiology, Tenri Hospital, Tenri, Japan.
  • Division of Cardiology, Takanohara Central Hospital, Nara, Japan.
  • Division of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.

ORCID-Profile: Masaharu Akao

Förderung

  • Boehringer Ingelheim
  • Bayer Healthcare
  • Pfizer
  • Bristol-Myers Squibb
  • Astellas Pharma
  • AstraZeneca
  • Daiichi Sankyo
  • Novartis Pharma

Zitieren

APA

Hamatani, Y., Iguchi, M., Kato, T., Inuzuka, Y., Tamaki, Y., Ozasa, N., Kawaji, T., Esato, M., Tsuji, H., Wada, H., Hasegawa, K., Abe, M., Kimura, T., Ono, K., Akao, M., & Fushimi AF Registry and KCHF Registry investigators (2025). Importance of Non-Cardiovascular Comorbidities in Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. https://doi.org/10.1002/ehf2.15093

Vancouver

Hamatani Y, Iguchi M, Kato T, Inuzuka Y, Tamaki Y, Ozasa N, et al. Importance of Non-Cardiovascular Comorbidities in Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. 2025. doi:10.1002/ehf2.15093

BibTeX
@article{Hamatani2025,
  author = {Hamatani, Yasuhiro and Iguchi, Moritake and Kato, Takao and Inuzuka, Yasutaka and Tamaki, Yodo and Ozasa, Neiko and Kawaji, Tetsuma and Esato, Masahiro and Tsuji, Hikari and Wada, Hiromichi and Hasegawa, Koji and Abe, Mitsuru and Kimura, Takeshi and Ono, Koh and Akao, Masaharu and Fushimi AF Registry and KCHF Registry investigators, Fushimi AF Registry and KCHF Registry investigators},
  title = {Importance of Non-Cardiovascular Comorbidities in Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15093}
}
Kostenlos starten →